Propanc Biopharma Inc

PPCB Healthcare Biotechnology

In the quarter to June 2026, EPS fell 99.6%, free cash flow fell 1,637.4% and total debt fell 21.4%, each against the same quarter a year earlier.

0.34 0.00 0.00%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Current Ratio
2.55 2.37 2.13 2.45

+8 more quarters

Net Debt/EBITDA
0.11 0.00 0.01 0.02
Debt/Assets
3.61% 3.25% 3.56% 2.92%
Debt/Equity
0.05 0.05 0.05 0.04
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.35 0.18 0.25 0.40
Capex/Depreciation
0.00 (0.33) (7.67) (25.00)
Interest Coverage
(124.81) (167.11) (61.94) (15.29)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.43) (1.27) (1.87) (3.94)
Cash per Share
0.74 0.49 1.05 1.22
Shareholders Equity per Share
8.37 10.96 19.56 29.11
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
8.37 10.96 19.56 29.11
Free Cash Flow
(1.60) (1.14) (1.00) (1.94)
Working Capital
5.19 4.75 4.08 5.19
Capital Expenditures
0.00 0.00 0.00 0.00
Net Current Asset Value
5.16 3.72 3.05 5.15
Other line items
Quick Ratio
0.25 0.13 0.16 0.17
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(1.43) (1.27) (1.87) (3.93)
Capex per Share
0.00 0.00 0.00 (0.01)
Average Receivables
0.01 0.01 0.01 0.01
Average Payables
1.19 1.05 1.09 1.16
Average Assets
16.21 18.43 7.60 9.02
Average Common Equity
11.65 13.96 3.15 5.13
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates · fundamentals updated 6 Oct 2026